Mayne Pharma Group Limited (MAYNF)
Mayne Pharma Group Limited operates in the Drug Manufacturers - General industry of the Healthcare sector, headquartered in Salisbury South, SA, AU. The stock last traded at $2.31, up 0.43% on the session, giving a market capitalisation of $187.7M. On trailing twelve-month figures it carries a trailing P/E of -3.06, a net margin of -20.4%. Its beta of 1.00 implies it has historically moved less than the broad market.
Mayne Pharma Group Limited is an Australian-headquartered specialty pharmaceutical enterprise, engaged in the development, production, and marketing of both patented (branded) and generic drug formulations. Its commercial reach spans Australia, New Zealand, North America (covering the United States and Canada), Europe, and Asia. The company's operations are divided into four main segments: Metrics Contract Services, International, Branded Products, and Portfolio Products. Beyond its own product lines, Mayne Pharma offers sophisticated oral drug delivery technologies and comprehensive contract services—including pharmaceutical development, manufacturing, and analytical testing—to other businesses. Its strategic focus areas for specialty product distribution include dermatology, women's health, and infectious disease treatments. Originally established in 2005, the company operated under the name Halcygen Pharmaceuticals Limited before rebranding to Mayne Pharma Group Limited in November 2010. Its principal office is located in Salisbury South, Australia.
Mayne Pharma Group Limited is most often compared with the following Healthcare names: